source
- Cytospire secures $83 million to develop pan-gamma delta T-cell engagersCytospire, a British biotechnology startup, announced it raised £61 million, about $83 million, to fund the development of a new type of T-cell engager therapy. The company is targeting a "pan-gam…
- Latus Bio raises $97 million to advance gene therapies for Huntington’s and Batten diseaseLatus Bio announced closing a $97 million Series A round, including a $43 million extension to a prior $54 million raise. Funding was led by 8VC and included eight other investors such as DCVC Bio…